Elevar Therapeutics to Participate in ASCO 2023 and BIO 2023; New Jersey-based Company Secures State License as It Builds Toward Commercialization
Presentation details are as follows:
- Presentation details are as follows:
Elevar also will attend BIO 2023, to be held June 5-8 at the Boston Convention & Exhibition Center in Boston, as it seeks partnership for global commercialization of rivoceranib.
- In March, Elevar announced its move to a new corporate headquarters in Fort Lee, New Jersey.
- It has now obtained its New Jersey Resident State Facility Inspection Report and is a licensed pharmaceutical wholesaler in the state, part of its strategic nationwide state licensing process.
- We look forward to gaining licensure in every U.S. state as we prepare for commercialization of rivoceranib.”